MP1032 plus standard of care versus placebo plus standard of care in hospitalized patients with moderate to severe COVID-19

Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing MP1032 plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Proportion of patients with disease progression on Day 14. Started May 2021; status: completed.